Filing Details

Accession Number:
0001683168-22-004885
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-11 19:42:04
Reporting Period:
2022-07-07
Accepted Time:
2022-07-11 19:42:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
704562 Avid Bioservices Inc. CDMO Pharmaceutical Preparations (2834) 953698422
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1346342 R Daniel Hart 2642 Michelle Drive, Suite 200
Tustin CA 92780
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Acquisiton 2022-07-07 11,673 $0.00 40,893 No 4 M Direct
Common Stock, $0.001 Par Value Disposition 2022-07-08 4,150 $17.53 36,743 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Stock Units Disposition 2022-07-07 11,673 $0.00 11,673 $0.00
Common Stock Performance Stock Units Disposition 2022-07-07 4,540 $0.00 4,540 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
36,968 No 4 M Direct
32,428 No 4 D Direct
Footnotes
  1. Each Performance Stock Unit ("PSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock.
  2. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the PSUs described in footnote 4. This sale does not represent a discretionary trade by the reporting person.
  3. Represents a weighted average sales price per share. These shares were sold at prices ranging from $17.53 to $17.62. The Reporting Person has provided to the Issuer, and hereby undertakes to provide the SEC staff or a security holder of the Issuer, upon request, information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The vesting of the PSUs granted to the reporting person on July 9, 2021 is subject to the Issuer achieving certain fiscal year financial milestones over three (3) fiscal year performance periods beginning with the Issuer's fiscal year ending April 30, 2022 and continuing through the fiscal year ending April 30, 2024 (each a "Performance Period"). Subject to the Issuer attaining the applicable fiscal year milestones, 1/3rd of the PSUs will vest on the last day of each fiscal year during the Performance Period, subject to the reporting person's continuous service to the Issuer on such vesting dates. The number of PSUs initially reported by the reporting person was based on a maximum 200% achievement of each milestone during each Performance Period (the "Maximum Performance Target"). In the event that a milestone is achieved at a rate below the Maximum Performance Target, or is not achieved, the corresponding portion of the PSUs that do not vest will be forfeited.
  5. Vested PSUs settled into shares of the Issuer's Common Stock on the fifth business day following the chief financial officer's certification of the Issuer's achievement of the milestones for the Performance Period ended April 30, 2022.
  6. Represents the forfeiture of unearned PSUs for the Performance Period ended April 30, 2022.